BioCentury
ARTICLE | Top Story

Generic Copaxone launched after CAFC invalidates Teva patent

June 19, 2015 1:19 AM UTC

The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) launched once-daily multiple sclerosis (MS) drug Glatopa glatiramer acetate in the U.S. after the U.S. Court of Appeals for the Federal Circuit (CAFC) invalidated the last U.S. patent for once-daily Copaxone from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).

Glatopa is the first FDA-approved generic version of Copaxone. Sandoz developed Glatopa in partnership with Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) (see BioCentury Extra, April 16). ...